Mediolanum International Funds Ltd Has $15.98 Million Stock Position in Cigna Group $CI

Mediolanum International Funds Ltd boosted its holdings in shares of Cigna Group (NYSE:CI) by 60.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,958 shares of the health services provider’s stock after acquiring an additional 18,509 shares during the quarter. Mediolanum International Funds Ltd’s holdings in Cigna Group were worth $15,975,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in CI. Price T Rowe Associates Inc. MD increased its stake in Cigna Group by 10.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,056,806 shares of the health services provider’s stock valued at $3,966,690,000 after buying an additional 1,094,327 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Cigna Group by 1.1% in the second quarter. Massachusetts Financial Services Co. MA now owns 11,778,472 shares of the health services provider’s stock worth $3,893,727,000 after acquiring an additional 123,479 shares during the last quarter. Dodge & Cox raised its holdings in shares of Cigna Group by 1.3% during the first quarter. Dodge & Cox now owns 8,889,733 shares of the health services provider’s stock worth $2,924,722,000 after acquiring an additional 117,125 shares in the last quarter. GQG Partners LLC lifted its holdings in shares of Cigna Group by 21.5% during the 1st quarter. GQG Partners LLC now owns 4,886,674 shares of the health services provider’s stock valued at $1,607,716,000 after buying an additional 865,092 shares during the last quarter. Finally, Valeo Financial Advisors LLC grew its stake in shares of Cigna Group by 86,071.1% in the 2nd quarter. Valeo Financial Advisors LLC now owns 3,475,282 shares of the health services provider’s stock valued at $1,148,859,000 after buying an additional 3,471,249 shares in the last quarter. Institutional investors and hedge funds own 86.99% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CI. Guggenheim cut their price objective on shares of Cigna Group from $350.00 to $309.00 in a research report on Friday, October 31st. Jefferies Financial Group reiterated a “buy” rating and set a $310.00 price target on shares of Cigna Group in a report on Monday, November 3rd. Wall Street Zen upgraded shares of Cigna Group from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Cowen reaffirmed a “buy” rating on shares of Cigna Group in a report on Tuesday, November 4th. Finally, Leerink Partners dropped their target price on shares of Cigna Group from $300.00 to $270.00 in a report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cigna Group currently has a consensus rating of “Moderate Buy” and an average price target of $334.05.

Insider Buying and Selling at Cigna Group

In other Cigna Group news, CEO David Cordani bought 4,134 shares of the firm’s stock in a transaction dated Monday, November 3rd. The shares were bought at an average price of $241.88 per share, for a total transaction of $999,931.92. Following the completion of the acquisition, the chief executive officer owned 157,935 shares of the company’s stock, valued at approximately $38,201,317.80. This trade represents a 2.69% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Brian C. Evanko sold 5,368 shares of the firm’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $300.00, for a total transaction of $1,610,400.00. Following the completion of the sale, the insider owned 51,182 shares of the company’s stock, valued at $15,354,600. The trade was a 9.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.70% of the company’s stock.

Cigna Group Trading Up 3.2%

Shares of CI opened at $278.12 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 0.65. The stock has a market cap of $74.29 billion, a PE ratio of 15.18, a PEG ratio of 0.88 and a beta of 0.44. Cigna Group has a 1 year low of $239.51 and a 1 year high of $350.00. The stock has a 50 day simple moving average of $286.74 and a 200-day simple moving average of $299.18.

Cigna Group (NYSE:CI) last announced its quarterly earnings results on Thursday, October 30th. The health services provider reported $7.83 earnings per share for the quarter, beating analysts’ consensus estimates of $7.64 by $0.19. The firm had revenue of $69.57 billion for the quarter, compared to analysts’ expectations of $66.40 billion. Cigna Group had a return on equity of 18.80% and a net margin of 1.92%.The business’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business posted $7.51 earnings per share. Cigna Group has set its FY 2025 guidance at 29.600- EPS. On average, sell-side analysts predict that Cigna Group will post 29.77 EPS for the current fiscal year.

Cigna Group Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Thursday, December 4th will be issued a dividend of $1.51 per share. This represents a $6.04 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Thursday, December 4th. Cigna Group’s dividend payout ratio (DPR) is currently 26.64%.

Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.